Sarepta Therapeutics Shares Drop 26% Following Third Patient Death in Gene Therapy Trial
TL;DR Summary
Sarepta Therapeutics' stock plummeted after a third patient died from acute liver failure following gene therapy treatment, raising safety concerns and impacting investor confidence amid ongoing restructuring and regulatory scrutiny.
- Sarepta Therapeutics Crashes 26% After A Third Gene Therapy Patient Dies Investor's Business Daily
- Patient dies in Sarepta gene therapy trial, adding to safety concerns STAT
- Sarepta Says Another Patient Died After Receiving Gene Therapy Bloomberg
- Sarepta Reports a Third Gene-Therapy Related Patient Death BioSpace
- Sarepta Therapeutics Stock Tumbles on Report of Third Death in Clinical Trial Yahoo Finance
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
3 min
vs 4 min read
Condensed
96%
697 → 30 words
Want the full story? Read the original article
Read on Investor's Business Daily